Literature DB >> 21427552

Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?

Valentina Fodale1, Mariaelena Pierobon, Lance Liotta, Emanuel Petricoin.   

Abstract

Chemotherapy treatments are considered essential tools to defeat cancer progression and dissemination to improve patients' quality of life and survival. Although most malignancies initially respond to chemotherapeutic treatments, after an unpredictable period, tumor cells develop mechanisms of resistance to the treatment. Different cell compartments are involved in the mechanism of chemoresistance, and multiple mechanisms can be activated by single cells at different times of the cancer progression. Alteration of drug metabolism, derangement of intracellular pathways' signaling, cross-talk between different membrane receptors, and modification of apoptotic signaling and interference with cell replication are all mechanisms that the cell uses to overcome the effect of pharmacological compounds.In this review, we describe different adaptation, mostly at the level of the proteome, which cancer cells use to develop resistance to cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21427552      PMCID: PMC5558433          DOI: 10.1097/PPO.0b013e318212dd3d

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  64 in total

1.  Lung resistance-related protein: determining its role in multidrug resistance.

Authors:  W S Dalton; R J Scheper
Journal:  J Natl Cancer Inst       Date:  1999-10-06       Impact factor: 13.506

Review 2.  Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

Authors:  J M Gee; J F Robertson; E Gutteridge; I O Ellis; S E Pinder; M Rubini; R I Nicholson
Journal:  Endocr Relat Cancer       Date:  2005-07       Impact factor: 5.678

Review 3.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin.

Authors:  M A Jordan
Journal:  Curr Med Chem Anticancer Agents       Date:  2002-01

4.  Role of the breast cancer resistance protein (ABCG2) in drug transport.

Authors:  Qingcheng Mao; Jashvant D Unadkat
Journal:  AAPS J       Date:  2005-05-11       Impact factor: 4.009

Review 5.  Tyrosine kinases as targets in cancer therapy - successes and failures.

Authors:  Peter Traxler
Journal:  Expert Opin Ther Targets       Date:  2003-04       Impact factor: 6.902

Review 6.  The epidermal growth factor receptor pathway: a model for targeted therapy.

Authors:  Maurizio Scaltriti; José Baselga
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

Review 7.  Mechanisms of drug resistance in cancer chemotherapy.

Authors:  Y A Luqmani
Journal:  Med Princ Pract       Date:  2005       Impact factor: 1.927

8.  Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.

Authors:  C Meijer; N H Mulder; H Timmer-Bosscha; W J Sluiter; G J Meersma; E G de Vries
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

9.  Ratio of 2'-deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate influences the commitment of human colon carcinoma cells to thymineless death.

Authors:  J A Houghton; D M Tillman; F G Harwood
Journal:  Clin Cancer Res       Date:  1995-07       Impact factor: 12.531

Review 10.  Sugar and fat - that's where it's at: metabolic changes in tumors.

Authors:  Christian D Young; Steven M Anderson
Journal:  Breast Cancer Res       Date:  2008-02-20       Impact factor: 6.466

View more
  72 in total

1.  Yet another function of p53--the switch that determines whether radiation-induced autophagy will be cytoprotective or nonprotective: implications for autophagy inhibition as a therapeutic strategy.

Authors:  Shweta Chakradeo; Khushboo Sharma; Aisha Alhaddad; Duaa Bakhshwin; Ngoc Le; Hisashi Harada; Wataru Nakajima; W Andrew Yeudall; Suzy V Torti; Frank M Torti; David A Gewirtz
Journal:  Mol Pharmacol       Date:  2015-02-09       Impact factor: 4.436

2.  Antitumor agents. 293. Nontoxic dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate (DDB) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs.

Authors:  Hsin-Yi Hung; Emika Ohkoshi; Masuo Goto; Kenneth F Bastow; Kyoko Nakagawa-Goto; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2012-05-21       Impact factor: 7.446

3.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Authors:  Thomas Clozel; ShaoNing Yang; Rebecca L Elstrom; Wayne Tam; Peter Martin; Matthias Kormaksson; Samprit Banerjee; Aparna Vasanthakumar; Biljana Culjkovic; David W Scott; Sarah Wyman; Micheal Leser; Rita Shaknovich; Amy Chadburn; Fabrizio Tabbo; Lucy A Godley; Randy D Gascoyne; Katherine L Borden; Giorgio Inghirami; John P Leonard; Ari Melnick; Leandro Cerchietti
Journal:  Cancer Discov       Date:  2013-08-16       Impact factor: 39.397

4.  Evolutionary dynamics in cancer therapy.

Authors:  Jessica J Cunningham; Robert A Gatenby; Joel S Brown
Journal:  Mol Pharm       Date:  2011-08-23       Impact factor: 4.939

Review 5.  Mechanisms of resistance to photodynamic therapy.

Authors:  A Casas; G Di Venosa; T Hasan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

6.  Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model.

Authors:  Charles H Lineweaver; Paul C W Davies; Mark D Vincent
Journal:  Bioessays       Date:  2014-07-14       Impact factor: 4.345

Review 7.  c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.

Authors:  Daniel Delitto; Eva Vertes-George; Steven J Hughes; Kevin E Behrns; Jose G Trevino
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 8.  Regulation of chemoresistance via alternative messenger RNA splicing.

Authors:  Scott T Eblen
Journal:  Biochem Pharmacol       Date:  2012-01-08       Impact factor: 5.858

9.  The impact of cell density and mutations in a model of multidrug resistance in solid tumors.

Authors:  James Greene; Orit Lavi; Michael M Gottesman; Doron Levy
Journal:  Bull Math Biol       Date:  2014-02-20       Impact factor: 1.758

10.  Co-delivery with nano-quercetin enhances doxorubicin-mediated cytotoxicity against MCF-7 cells.

Authors:  Akbar Minaei; Mehdi Sabzichi; Fatemeh Ramezani; Hamed Hamishehkar; Nasser Samadi
Journal:  Mol Biol Rep       Date:  2016-01-09       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.